Loading stock data…
Viatris Inc. (VTRS)
$16.88-0.06 (-0.35%)
Pre-Market$16.90+0.02 (+0.12%)· Last close Sep 4
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Viatris Inc. in the Healthcare sector is trading at $16.88 with a market capitalization of $19.4B. Wall Street consensus targets $18.50 (8 analysts), implying a +9.6% move over the next 12 months. The stock is currently near its 52-week high of $18.39, remaining 16.3% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +9.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.76B↑ | $3.52B↓ | $3.70B↓ | $3.76B↑ | $3.58B |
| Gross Profit | $1.46B↑ | $1.16B↑ | $1.15B↓ | $1.37B↑ | $1.33B |
| Operating Income | $73.70M↑ | -$20.20M↑ | -$157.50M↓ | $234.50M↑ | $185.40M |
| Net Income | -$118.80M↓ | $176.40M↑ | -$340.10M↓ | -$128.20M↓ | -$4.60M |
Peer Comparison
JNJUNHPFE
Fundamentals
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$19.39B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.88
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.84%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.88%
Volume
Today's trading volume
5.73M
Recent News
Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks
The recent breakout of Moderna reminded investors that AI stocks aren’t the only destination to make money. Healthcare and biotech stocks offer promising long-term opportunities if chosen wisely. We ran an analysis based on Insider Monkey’s proprietary database of over 900 hedge funds to see which healthcare stocks trading under $20 billionaire-led funds were holding […]
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris
Amphastar Pharmaceuticals, Sandoz and Viatris are positioned to benefit from new launches, biosimilars and a shift toward higher-value generics.
3 Cash-Producing Stocks That Concern Us
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough?
Why recent generic drug earnings matter for Viatris stock Recent earnings across the generic drug industry highlighted steady demand alongside pricing and supply challenges, putting fresh attention on how Viatris (VTRS) is using new launches, product mix, and cost discipline to support its business. At a share price of US$16.34, Viatris has seen some short term pressure, with the 1 day share price return declining 3.26% and the 1 month share price return down 8.31%. However, the year to date...
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris
Cavendish has reiterated its buy rating on Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) following the pharmaceutical company's agreement to take full commercial control of its main United States (US) product from Viatris. The broker kept its target price at 23 pence, implying potential...